MOB — Moberg Pharma AB (publ) Share News
0.000.00%
Last trade - 00:00- SEK434.29m
- SEK213.93m
- SEK13.54m
Brief: Moberg Pharma Enters Financing Agreement For Further Investments In MOB-015
Brief: Moberg Pharma Q2 EBITDA Loss Narrows To SEK 4.2 Million
Brief: Moberg Pharma: Expert Evaluation Clarifies Phase 3 Results And Provides Strong Support For Mob-015
Brief: Finansinspektionen: Zimbrine Holding Sells 1,774,068 Shares In Moberg Pharma
Brief: Moberg Pharma Comments On The Results Of The North American Phase 3 Study With Mob-015
Brief: Moberg Pharma Meets Primary Endpoint For MOB-015 In Phase 3 Study For Treatment Of Onychomycosis
Brief: Moberg Pharma Q1 EBIT Rises To SEK 41.8 Mln
Brief: Moberg Pharma And Dongkoo Sign Agreement In Republic Of Korea
Brief: Moberg Pharma: Sarah Hellerfelt To Leave Position As CFO
Brief: Moberg Pharma Says Proposes To Pay Shareholders SEK 46.5/Shr And Repays MOB-015 Loan
Brief: Moberg Pharma And Taisho Sign Exclusive License Agreement For Mob-015 In Japan
Brief: Moberg Pharma Q2 EBITDA Loss Narrows To SEK 8.5 Mln
Brief: Moberg Pharma Q1 EBITDA Swings To Profit Of SEK 7.3 Million
Brief: Moberg Pharma Board Of Directors And Nomination Committee Have Proposed Appointment Of Anna Ljung As New CEO
Brief: Moberg Pharma Completes Divestment The OTC-Business For $155 Mln
Moberg Pharma: Record high after deal with Bayer, strong Q4
Swedish stocks: Seen opening higher in line with Europe
Brief: Moberg Pharma Reports Qtrly Diluted Earnings Per Share SEK 0.62
Brief: Moberg Pharma divests its OTC-business